Selective sensitivity of Ph-like B-cell acute lymphoblastic leukemia to BRG1 inhibition identifies a therapeutic vulnerability

V S S Abhinav Ayyadevara, Ria Perencsik, Shreya Patil, Shikha Gaur, Ashley Paik, Monika Toma, Gerald Wertheim, Huimin Geng, Tomasz Skorski, Srividya Swaminathan, Christian Hurtz · 2026

Read Selective sensitivity of Ph-like B-cell acute lymphoblastic leukemia to BRG1 inhibition identifies a therapeutic vulnerability by V S S Abhinav Ayyadevara, Ria Perencsik, Shreya Patil, Shikha Gaur, Ashley Paik, Monika Toma, Gerald Wertheim, Huimin Geng, Tomasz Skorski, Srividya Swaminathan, Christian Hurtz (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13421310.txt.

Description

Abhinav Ayyadevara and ten colleagues write to the editor in 2026 about a drug target in Ph-like B-cell acute lymphoblastic leukaemia. This high-risk subtype relapses often. Three-year survival sits near 65 percent. They focus on BRG1, a motor protein of the SWI/SNF chromatin complex that early B cells need.

In solid tumours, losing a related gene makes cancers depend on BRG1's partner protein, yet blood cancers show the reverse pattern: they depend on BRG1 itself. The team's experiments found this leukaemia subtype selectively sensitive to BRG1 blockade. They present that sensitivity as a therapeutic vulnerability worth exploiting, since options after relapse remain poor.

Catalog record

CREATORV S S Abhinav Ayyadevara, Ria Perencsik, Shreya Patil, Shikha Gaur, Ashley Paik, Monika Toma, Gerald Wertheim, Huimin Geng, Tomasz Skorski, Srividya Swaminathan, Christian Hurtz
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE16625
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13421310

Browse the full library · About the Tower of Babel